Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512278 | 1.00 | MAPT (0.52) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL14933994 | 0.91 | GPR119 (0.49) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL17147017 | 0.91 | GPR119 (0.48) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL14915852 | 0.85 | POLB (0.48) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL14915853 | 0.85 | POLB (0.48) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL14930420 | 0.84 | GPR119 (0.51) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL29741868 | 0.83 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL1392727 | 0.82 | MAPT (0.68) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL29435691 | 0.82 | MAPT (0.68) | MAPTALDH1A1LMNAGPR119POLB | |
| SCHEMBL29742102 | 0.82 | MAPT (0.42) | MAPTALDH1A1LMNAGPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4480482-A2 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | ABBVIE INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4249073-B1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2023183811-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4249073-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-107011348-B | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | 霍夫曼-拉罗奇有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9782405-B2 | Heteroaryl pyridone and aza-pyrodine compounds | GENENTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3002284-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| CN-104125959-A | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | HOFFMANN LA ROCHE | 2014-10-29 | — | — | CN | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | MAPT 4765/4885ALDH1A1 2025/4885LMNA 3332/4885 |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | MAPT 4765/4885ALDH1A1 2025/4885LMNA 3332/4885 |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | MAPT 2440/4885ALDH1A1 4684/4885LMNA 2047/4885 |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | MAPT 2440/4885ALDH1A1 4684/4885LMNA 2047/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MAPT 2050/4885ALDH1A1 4561/4885LMNA 2651/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MAPT 2050/4885ALDH1A1 4561/4885LMNA 2651/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | MAPT 3237/4885ALDH1A1 4251/4885LMNA 1756/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | MAPT 3237/4885ALDH1A1 4251/4885LMNA 1756/4885 |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | BTK, TYMP, LYN | MAPT 4765/4885ALDH1A1 2025/4885LMNA 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.